---
id: 065
title: Echinocandins Mechanism and Spectrum
category: antimicrobials
subcategory: echinocandins
tags: [echinocandins, caspofungin, micafungin, anidulafungin, candidemia, beta-glucan]
difficulty: medium
---

## Question

What is the mechanism and spectrum of echinocandins? Use the **"CANDI-CIDAL via β-GLUCAN"** mnemonic.

## Answer

### **"CANDI-CIDAL via β-GLUCAN" Mnemonic:**

**CANDI-CIDAL:**
- **C**aspofungin, micafungin, anidulafungin
- **A**ll *Candida* species (including azole-resistant)
- **N**o oral formulation (IV only)
- **D**estruction of fungal cell wall
- **I**nhibits β-glucan synthase

**CIDAL:**
- **C**idal for *Candida* (fungicidal)
- **I**V administration required
- **D**aily dosing
- **A**spergillus (fungistatic only)
- **L**imited spectrum (no Cryptococcus, Mucor)

**β-GLUCAN:**
- **β**-1,3-glucan synthase = target enzyme
- **G**lucans are essential cell wall component
- **L**ysis of fungal cell
- **U**nique mechanism (no cross-resistance)
- **C**ell wall disruption
- **A**ll three agents similar activity
- **N**o human analog (selective toxicity)

### **Mechanism of Action:**

**Target:** **β-1,3-glucan synthase** enzyme

**Process:**
1. **Noncompetitive inhibition** of β-1,3-glucan synthase
2. Blocks synthesis of **β-glucan** (essential fungal cell wall component, 30-60% of cell wall)
3. Cell wall instability → **cell lysis**
4. **Fungicidal** against *Candida* spp.
5. **Fungistatic** against *Aspergillus* spp.

**Selectivity:** Mammals don't have β-glucan or β-glucan synthase → **no toxicity to human cells**

### **Spectrum of Activity:**

| Organism | Activity | Notes |
|----------|----------|-------|
| ***Candida albicans*** | **Fungicidal** (excellent) | 1st-line for candidemia |
| ***C. glabrata*** | **Fungicidal** (excellent) | Better than fluconazole |
| ***C. krusei*** | **Fungicidal** (excellent) | Azole-resistant, echino-sensitive |
| ***C. auris*** | **Fungicidal** (excellent) | Most isolates susceptible |
| ***C. parapsilosis*** | ⚠️ **Higher MICs** | Still usually effective |
| ***Aspergillus*** spp. | Fungistatic | Salvage therapy, not 1st-line |
| ***Cryptococcus*** | ❌ **NO** activity | No β-glucan in capsule |
| **Mucorales** | ❌ **NO** activity | Different cell wall |
| **Endemic fungi** | ❌ **NO** activity | Use ampho B or azoles |

## Key Points

### **Three Echinocandins Comparison:**

| Feature | Caspofungin | Micafungin | Anidulafungin |
|---------|-------------|------------|---------------|
| **Dosing** | 70mg load → 50mg daily | 100-150mg daily | 200mg load → 100mg daily |
| **Metabolism** | Hepatic | Hepatic | **Non-hepatic** (spontaneous degradation) |
| **Dose adjust (renal)** | No | No | No |
| **Dose adjust (hepatic)** | **Yes** (reduce to 35mg) | Consider reduction | **No** |
| **Drug interactions** | Moderate (cyclosporine ↑ LFTs) | Few | **Fewest** |
| **FDA indications** | Candidemia, aspergillosis (salvage) | Candidemia, prophylaxis | Candidemia, esophageal candidiasis |

### **Clinical Indications (IDSA Guidelines):**

**First-Line:**
- **Candidemia** (all three echinocandins are 1st-line)
- **Invasive candidiasis**
- **Empiric therapy** for suspected invasive candidiasis in ICU

**Alternative/Salvage:**
- **Invasive aspergillosis** (salvage or combination therapy)
- **Candida esophagitis** (refractory to azoles)

**Prophylaxis:**
- High-risk neutropenic patients (micafungin approved)

### **Why Echinocandins are 1st-Line for Candidemia:**

1. **Fungicidal** (azoles are fungistatic)
2. **Broad *Candida* coverage** (including azole-resistant *C. glabrata*, *C. krusei*)
3. **Superior outcomes** vs ampho B or fluconazole (meta-analysis)
4. **Excellent safety profile** (minimal toxicity)
5. **No resistance** (very rare <1%)

### **Resistance Mechanisms (Rare <1%):**

**FKS mutations:**
- Mutations in *FKS1* or *FKS2* genes (encode β-glucan synthase subunits)
- Most common in *C. glabrata* (after prolonged echinocandin exposure)
- Clinical resistance still rare

### **Clinical Pearls:**
- **All three equally effective** for candidemia
- **IV only** (no oral formulation, poor bioavailability)
- **Minimal toxicity** (safest antifungal class)
- **Anidulafungin** preferred if liver dysfunction (no hepatic metabolism)
- **Higher MICs** for *C. parapsilosis* but usually still effective clinically
- **Do NOT cover Cryptococcus** (must use azole or ampho B)

## Sources

- [PMC3352072: Pharmacology and Metabolism of Echinocandins]
- [PMC3352073: Treatment of Invasive Candidiasis with Echinocandins]
- [LiverTox: Echinocandins Hepatotoxicity]
- [PMC1936290: Comparison of Echinocandin Antifungals]

## Media

N/A
